Sodium glucose co-transporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors and the risk of ventricular arrhythmia among patients with type 2 diabetes: A population-based cohort study. [PDF]
Diabetes Obes MetabTang WC +5 more
europepmc +1 more source
Sodium glucose co-transporter 2 inhibitors safety depending on their adverse drug reactions and glucose monitoring parameters in type 2 diabetes mellitus. [PDF]
Indian J PharmacolBellapu D, Darwin R.
europepmc +1 more source
Sodium-glucose co-transporter-2 inhibitors vs metformin in reducing osteoarthritis risk: a retrospective cohort study of health insurance claims and check-up data. [PDF]
JBMR PlusHatano M +7 more
europepmc +1 more source
Sodium-glucose co-transporter 2 inhibitors use and the risks of genital and urinary tract infection: What should we know? [PDF]
Tzu Chi Med JWu DA, Hsu BG, Lin YL.
europepmc +1 more source
Sodium Glucose Co-transporter 2 Inhibitors and Heart Failure
The American Journal of Cardiology, 2019 Sodium-glucose co-transporter 2 (SGLT2) receptors are primarily located in the proximal convoluted tubule of the nephron. These receptors are responsible for almost 90% to 95% of tubular reabsorption of the glucose in the nephron. In patients with diabetes mellitus, due to upregulation of SGLT2 receptors, glucose reabsorption is further increased.
Raktim K. Ghosh +8 more
openaire +6 more sources
Related searches:
Sodium‐glucose co‐transporter 2 inhibitors and hematopoiesis
Journal of Cellular Physiology, 2022AbstractMany patients with diabetes mellitus, especially those with chronic kidney disorders, have some degree of anemia due to a spectrum of causes and underlying pathophysiologic pathways. As such, enhancement in erythropoiesis is important in these patients.
Habib Yaribeygi +5 more
openaire +2 more sources
Sodium–glucose co-transporter-2 inhibitors
2022Abstract This chapter studies the use of aldosterone antagonists, also known as Mineralocorticoid Receptor Antagonists (MRAs), in chronic heart failure (CHF). Overall, the results for aldosterone blockade in CHF due to left ventricular systolic dysfunction (LVSD) — now called heart failure with reduced ejection fraction (HF-REF) — have ...
Matthew M. Y. Lee +2 more
openaire +1 more source
The unexpected benefits of sodium glucose co-transporter 2 (SGLT2) inhibitors
New Zealand Medical Journal, 2022The sodium glucose co-transporter 2 (SGLT2) inhibitor empagliflozin is currently funded in New Zealand for management of patients with type 2 diabetes who have an HbA1c >53mmol/mol and a high cardiovascular (CV) risk. Large clinical trials now provide strong evidence that SGLT2 inhibitors decrease the risk of cardiovascular death, heart failure ...
Chok G, Chan, Ralph, Stewart
openaire +2 more sources
Sodium glucose co-transporter 2 inhibitors and their nephroprotective potential
Clinical Nephrology, 2017Chronic kidney disease among patients with diabetes is on the rise. The sodium glucose co-transporters 2 inhibitors are a new class of glucose-lowering agents, which act through a novel mechanism by producing a decline in glucose reabsorption in the kidney, thereby increasing glucosuria and decreasing serum glucose levels.
Natalia G, Vallianou +2 more
openaire +2 more sources
Sodium-glucose co-transporter 2 inhibitors and Sarcopenia: A controversy that must be solved
Clinical Nutrition, 2023Diabetes mellitus is a risk factor for muscle loss and sarcopenia. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) or "gliflozins" are one of the newest anti-hyperglycemic drugs. They reduce blood glucose levels by inhibiting renal glucose reabsorption in the early proximal convoluted tubule. Various randomized trials showed that SGLT2i have cardio-
Baris Afsar, Rengin Elsurer Afsar
openaire +3 more sources